GNPX
Genprex, Inc. Common Stock
Nasdaq · usd
Stock performance
How Genprex, Inc. Common Stock (GNPX) stock has performed from one day to one year, with its 52-week range.
- 1D
- -8.65%
- 1W
- -7.77%
- 1M
- -9.95%
- YTD
- -95.06%
- 1Y
- -97.66%
- 52-wk range
- $1.71 – $93.94
Key statistics
Today's trading snapshot for GNPX: day range, open, previous close, volume and market cap.
- Day range
- —
- Open
- —
- Prev close
- $1.90
- Volume
- 0
- Market cap
- $1.56M
- Shares out
- 819.71K
Valuation and profitability ratios: P/E, P/S, ROE
Valuation and profitability ratios for Genprex, Inc. Common Stock: P/E, P/S, P/B, ROE and more.
- P/E
- —
- P/S
- —
- P/B
- 0.12
- P/FCF
- —
- ROE
- -111.5%
- ROA
- -96.3%
- Debt/Equity
- 0.00
- Div yield
- 0.00%
As of Nov 13, 2026
8-K filings
Material corporate events Genprex, Inc. Common Stock has disclosed to the SEC on Form 8-K.
- Partnership or collaborationNov 5, 2026
In collaboration with and pursuant to a sponsored research agreement with Meharry Medical College in Nashville, Tennessee, Genprex has been exploring aspects of REQORSA biology, including mitochondrial metabolism and molecular aging and their potential relationship to cancer.
- Partnership or collaborationOct 28, 2026
Genprex established a sponsored research collaboration with Meharry Medical College (Nashville, Tennessee) in 2024 to investigate aspects of REQORSA biology, including mitochondrial metabolism and molecular aging and their potential relationship to cancer.
- Partnership or collaborationAug 18, 2026
Genprex, Inc. issued a press release announcing it had entered into a development and manufacturing agreement with a leading U.S. based clinical and commercial Contract Development and Manufacturing Organization ("CDMO") to initiate the manufacturing scale-up of its diabetes gene therapy program. This strategic selection allows for the transition of the Company's therapeutic candidate from research-grade production to clinical and commercial-ready output.
- Listing compliance regainedAug 5, 2026
On August 4, 2026, the Company was formally notified that the Panel determined that the Company has regained compliance with the Bid Price Requirement. The Panel further informed the Company that until December 7, 2026, which represents the full extent of the Panel's discretion in this matter with respect to the Bid Price Requirement, the Company must maintain a closing bid price at or above $1.00 for each trading day.
- Partnership or collaborationAug 3, 2026
Genprex, Inc. issued a press release announcing its collaboration with Roche Diagnostics to validate biomarkers for patient selection in clinical trials for non-small cell lung cancer ('NSCLC'). Building on promising preclinical and clinical data, this collaboration intends to refine patient identification using TROP2 as a biomarker.
Dividend history and stock splits
Genprex, Inc. Common Stock's recent dividend payments and stock splits.
Dividends
No recent dividends.
Splits
- 1-for-22Jul 16, 2026
- 1-for-50Oct 21, 2025
- 1-for-40Feb 2, 2024
GNPX short interest
How heavily GNPX is shorted: shares short, days to cover and average daily volume.
- Days to cover
- 1.0
- Short interest
- 123.26K
- Avg volume
- 170.47K
As of · reported to FINRA twice monthly.
GNPX news
The latest news and headlines about Genprex, Inc. Common Stock (GNPX).
- Congressman Who Bought Small-Cap Stocks In 2025 Is Back With New 2026 Pick: Here's What He's BuyingneutralBenzinga· Feb 25, 2026
- Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer TherapeuticspositiveBenzinga· Sep 9, 2024
- Genprex (GNPX) Expands SCLC Study of Key Candidate, Stock UpZacks Investment Research· Apr 4, 2024
- Why United Natural Foods Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day SessionBenzinga· Mar 6, 2024
- Dow Turns Lower; Federal Reserve Keeps Rates UnchangedBenzinga· Jan 31, 2024
Frequently asked questions
What is the Genprex, Inc. Common Stock (GNPX) stock price today?
Massive provides real-time and historical Genprex, Inc. Common Stock (GNPX) quotes via REST API, WebSocket and MCP.
What is Genprex, Inc. Common Stock?
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and…
What is the short interest in GNPX?
As of Oct 30, 2026, GNPX has 123.26K shares short and 1.0 days to cover.
What exchange is GNPX listed on?
Genprex, Inc. Common Stock (GNPX) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.
Build with AI
Build an analysis of GNPX with your agent
Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.
Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a GNPX analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.